Dr. Nick Sireau is Executive Chairman and co-founder of Serenatis Bio, a Cambridge-based biotechnology company developing novel treatments for obsessive-compulsive disorder (OCD). He is also the founder of Orchard OCD, an organisation dedicated to advancing OCD research and treatment. Nick brings both professional and personal experience to the development of new treatments for OCD, as well as extensive experience in biotech and patient advocacy. He previously led clinical development work that resulted in the first approved treatment for alkaptonuria, a rare genetic disease affecting his own children.
Hannah Ellis is the Communications Officer at Serenatis Bio, where she is responsible for the company’s public outreach. With a passion for science communication, she is committed to correcting the narrative around OCD and broadening the discussion to help raise awareness of the need for better understanding, research and treatment.
Scientific progress only really matters if it changes what life looks like for those living with OCD. That’s because for someone who has spent years losing hours to their obsessions and compulsions, meaningful progress should mean a significant change in their lives.